World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
57
Citations
12541
World Ranking
3616
National Ranking
134

Thorbald van Hall publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Thorbald van Hall sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 147 publications — 15th percentile

15% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Thorbald van Hall D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Thorbald van Hall sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 57 D-Index — 28th percentile

28% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Thorbald van Hall is affiliated with Leiden University Medical Center in the Netherlands. Their research focuses primarily on medicine, immunology, and microbiology, with a particular emphasis on immunology and oncology as key subfields.

The main topics of van Hall's work include:

  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • Monoclonal and Polyclonal Antibodies Research
  • Immune cells in cancer
  • Virus-based gene therapy research

Their recent publications demonstrate involvement in exploring immune checkpoints, tumor microenvironments, and immune activation in cancer. Notable papers include:

  • "The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes" (2020, Cancer Cell)
  • "The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment" (2020, Clinical Cancer Research)
  • "Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors" (2021, Cancers)
  • "Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model" (2022, Gut)
  • "Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy" (2024, Cancer Cell)

Van Hall has frequently published in journals such as:

  • Journal for ImmunoTherapy of Cancer
  • Cancer Immunology Research
  • Cancer Cell
  • Regular and Young Investigator Award Abstracts
  • Cancers

Collaborative research features several frequent coauthors, including:

  • Sjoerd H. van der Burg
  • Jim Middelburg
  • Marjolein Sluijter
  • Marit J van Elsas
  • Christianne Groeneveldt

Their work spans various aspects of immune cell behavior within the tumor setting, with a focus on checkpoint pathways, T cell immunity, and macrophage activation relevant to therapeutic interventions in cancer. The research also addresses challenges related to bispecific antibody therapies and immune system activation mechanisms.

Best Publications

  • Therapeutic cancer vaccines

    Cornelis J.M. Melief;Thorbald van Hall;Ramon Arens;Ferry Ossendorp

  • Vaccines for established cancer: overcoming the challenges posed by immune evasion.

    Sjoerd H. van der Burg;Ramon Arens;Ferry Ossendorp;Thorbald van Hall

  • The urgent need to recover MHC class I in cancers for effective immunotherapy

    Federico Garrido;Natalia Aptsiauri;Elien M Doorduijn;Angel M Garcia Lora

  • The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes

    Floris Dammeijer;Mandy van Gulijk;Evalyn E. Mulder;Melanie Lukkes

  • Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein.

    J. P. Medema;J. De Jong;T. Van Hall;C. J. M. Melief

  • M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells.

    Moniek Heusinkveld;Peggy J. de Vos van Steenwijk;Renske Goedemans;Tamara H. Ramwadhdoebe

  • Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.

    Marieke F. Fransen;Mark Schoonderwoerd;Philipp Knopf;Marcel G.M. Camps

  • NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.

    Nadine van Montfoort;Linda Borst;Michael J. Korrer;Marjolein Sluijter

  • DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer Cells

    Mattias Carlsten;Niklas K. Björkström;Håkan Norell;Yenan Bryceson

  • Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes

    Michel P.M. Vierboom;Hans W. Nijman;Rienk Offringa;Ellen I.H. van der Voort

  • Monalizumab: inhibiting the novel immune checkpoint NKG2A

    Thorbald van Hall;Pascale André;Amir Horowitz;Dan Fu Ruan

  • Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.

    Rodney A. Rosalia;Esther D. Quakkelaar;Anke Redeker;Selina Khan

  • HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes

    Marloes Jm Gooden;Margit H Lampen;Ekaterina S Jordanova;Ninke Leffers

  • Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells.

    Selina Khan;Martijn S. Bijker;Jimmy J. Weterings;Hans J. Tanke

  • The NKG2A - HLA-E axis as a novel checkpoint in the tumor microenvironment

    Linda Borst;Sjoerd H van der Burg;Thorbald van Hall

  • Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants

    Thorbald van Hall;Elisabeth Z Wolpert;Peter van Veelen;Sandra Laban

  • Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity

    Nadine van Montfoort;Marcel G. Camps;Selina Khan;Dmitri V. Filippov

  • PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.

    Jan Willem Kleinovink;Koen A. Marijt;Mark J. A. Schoonderwoerd;Thorbald van Hall

  • Dendritic Cells Break Tolerance and Induce Protective Immunity against a Melanocyte Differentiation Antigen in an Autologous Melanoma Model

    Marco W. J. Schreurs;Andreas A. O. Eggert;Annemiek J. de Boer;Joost L. M. Vissers

  • Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.

    Floris Dammeijer;Lysanne A. Lievense;Margaretha E H Kaijen-Lambers;Menno van Nimwegen

  • Differential Influence on Cytotoxic T Lymphocyte Epitope Presentation by Controlled Expression of Either Proteasome Immunosubunits or Pa28

    Thorbald van Hall;Alice Sijts;Marcel Camps;Rienk Offringa

Frequent Co-Authors

Sjoerd H. van der Burg
Sjoerd H. van der Burg Leiden University Medical Center
Ferry Ossendorp
Ferry Ossendorp Leiden University Medical Center
Cornelis J. M. Melief
Cornelis J. M. Melief ISA Pharmaceuticals (Netherlands)
Rienk Offringa
Rienk Offringa German Cancer Research Center
Martine J. Jager
Martine J. Jager Leiden University Medical Center
Ramon Arens
Ramon Arens Leiden University Medical Center
Peter A. van Veelen
Peter A. van Veelen Leiden University Medical Center
Ekaterina S. Jordanova
Ekaterina S. Jordanova Vrije Universiteit Amsterdam
Jan W. Drijfhout
Jan W. Drijfhout Leiden University Medical Center
J. Sjef Verbeek
J. Sjef Verbeek Leiden University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various healthcare roles, many of which can be pursued through specialized online programs. For those interested in advancing their clinical expertise alongside immunological knowledge, an nurse practitioner accelerated program offers a fast-tracked route to becoming a licensed nurse practitioner.

Individuals without prior nursing experience can explore flexible options like online RN programs for non nurses in Florida, designed to smoothly transition students into registered nursing careers. These programs often integrate foundational science courses relevant to Immunology.

If accessibility is a priority, the easiest accelerated nursing programs provide manageable admission requirements and quicker completion timelines, ideal for students eager to enter the healthcare workforce promptly.

For entry-level nursing roles that complement immunological expertise, consider enrolling in accredited LPN programs easy to get into. These pathways offer foundational clinical skills and can serve as stepping stones to higher degrees in immunology-related fields.

Best Scientists Citing Thorbald van Hall

Trending Scientists

Recently Published Articles